Cargando…
Prolonged sulforaphane treatment does not enhance tumorigenesis in oncogenic K-ras and xenograft mouse models of lung cancer
BACKGROUND: Sulforaphane (SFN), an activator of nuclear factor erythroid-2 related factor 2 (Nrf2), is a promising chemopreventive agent which is undergoing clinical trial for several diseases. Studies have indicated that there is gain of Nrf2 function in lung cancer and other solid tumors because o...
Autores principales: | Kombairaju, Ponvijay, Ma, Jinfang, Thimmulappa, Rajesh K, Yan, Shengbin G, Gabrielson, Edward, Singh, Anju, Biswal, Shyam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424666/ https://www.ncbi.nlm.nih.gov/pubmed/22919281 http://dx.doi.org/10.4103/1477-3163.98459 |
Ejemplares similares
-
Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial
por: Wise, Robert A., et al.
Publicado: (2016) -
Correction: Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial
por: Wise, Robert A., et al.
Publicado: (2017) -
Sos-mediated cross activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis
por: Jeng, Hao-Hsuan, et al.
Publicado: (2012) -
AAV9-mediated telomerase activation does not accelerate tumorigenesis in the context of oncogenic K-Ras-induced lung cancer
por: Muñoz-Lorente, Miguel A., et al.
Publicado: (2018) -
Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas
por: Tran, Phuoc T., et al.
Publicado: (2008)